In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report), with a price target of $22.00. The company’s shares closed yesterday at $18.87.
Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Clearside Biomedical, and First Wave Bio. According to TipRanks, Chen has an average return of -29.6% and a 25.97% success rate on recommended stocks.
In addition to H.C. Wainwright, Bausch + Lomb Corporation also received a Buy from Bank of America Securities’s Craig Bijou in a report issued on August 2. However, yesterday, Barclays reiterated a Hold rating on Bausch + Lomb Corporation (NYSE: BLCO).
See the top stocks recommended by analysts >>
The company has a one-year high of $21.95 and a one-year low of $12.79. Currently, Bausch + Lomb Corporation has an average volume of 502.1K.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLCO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch & Lomb Corp is a global eye health company dedicated towards protecting and enhancing the gift of sight for millions of people around the world. It holds portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments.
Read More on BLCO:
- Bausch + Lomb price target raised to $19 from $18 at Barclays
- Bausch + Lomb files automatic mixed securities shelf
- Bausch + Lomb raises FY23 revenue view to $3.95B-$4.00B from $3.90B-$3.95B
- Bausch + Lomb reports Q2 adjusted EPS 18c, consensus 14c
- BLCO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
